Avoro Capital Advisors QURE Position
Active10-Fund ConvergenceAvoro Capital Advisors increased their position in uniQure N.V. (QURE) in Q4 2025, holding $147.2M worth of shares across 6,150,000 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
QURE is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.6% of float with 2.1 days to cover, indicating significant bearish positioning against Avoro Capital's long thesis.
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Full company profile →Short Interest
20.6%
2.1 days to cover
Avoro Capital Advisors QURE Position History
Frequently Asked Questions
Does Avoro Capital Advisors own QURE?
Yes. As of Q4 2025, Avoro Capital Advisors holds 6,150,000 shares of uniQure N.V. (QURE) valued at $147.2M. This data comes from their SEC 13F filing.
How many hedge funds own QURE?
10 specialist biotech hedge funds currently hold QURE, including RTW Investments, EcoR1 Capital, OrbiMed Advisors and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy QURE?
Avoro Capital Advisors's position in QURE was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's QURE position increasing or decreasing?
Avoro Capital Advisors increased their QURE position in the most recent quarter, adding 1,705,556 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
QURECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →